Immune Response of Cytotoxic T Lymphocytes and Possibility of Vaccine Development for Hepatitis C Virus Infection

Table 1

CTL epitopes identified by using different procedures.

(a) CTL epitopes identified by peptides overlapping by 10 residues and spanning the entire HCV sequence of genotype 1b

	HLA class I alleles	Region	Amino acid residues	Sequence	HLA restriction
Pt1	A*0207,2601 B*3501,4601 CW*0102,0303	NS3	1527–1546	WYELTPAETTVRLRAYLNTP	B*3501? A*2601?
		NS5B	2591–2605	KMALYDVVSTLPQAV	A*0207?
Pt2	A*2402,3303 B*4403,5401 CW*0803,1403	E1	332–351	LVVSQLLRIPQAVVDMVAGA	B*5401?
		NS3	1638–1656	THPITKFVMACMSADLEVV	B*5401?
		NS5B	2591–2605	KMALYDVVSTLPQAV	n.d.
Pt3	A*2602,3101 B*5101,5102 Cw1402,1502	NS3	1373–1380	IPFYGKAI	B*5101? B*5102?
Pt4	A*2402 B*0702,5201 Cw*0702,1202	E2	611–618	YPYRLWHY	n.d.
Pt5	A*1101,3101 B*6701,5101 Cw*0702,1401	NS5A	2290–2298	RPDYNPPLL	B*6701? B*5101?
Pt6	A*2402,2601 B*4002 Cw*0304	NS2	957–964	RDWAHAGL	B37
		NS5A	2122–2130	FTELDGVRL	n.d.
Pt7	A*2402,3303 B*0702,3501 Cw*0303,0702	Core	91–110	LGWAGWLLSPRGSRPSWGPT	A*3303? B*3501?
Pt8	A*2402 B*4801,5201 Cw*0803,1202	NS3	1643–1656	KFVMACMSADLEVV	n.d.
Pt9	A*2402 B*5201 Cw*1202	NS4	1760–1768	FWAKHMWNF	A*2402
		NS5B	2556–2564	TIMAKNEVF	n.d.
		NS5B	2803–2811	LTRDPTTPL	n.d.
Pt10	A*0201,0301 B*4402,4601 Cw*0102,0501	NS4	1958–1977	KRLHQWINEDCSTPCSGSWL	n.d.
Pt11	A*1101,2601 B*1501,5201 Cw*0401,1202	NS4	1858–1867	GVAGALVAFK	A*1101?
Pt12	A*2402 B*3501,4002 Cw*0303,0304	NS3	1618–1626	LHGPTPLLY	A*2402?

(b) CTL epitopes identified by HCV-derived synthetic peptides with binding motif of HLA-A24 [51]

	HLA class I alleles	Region	Amino acid residues	Sequence	HLA restriction
Pt13	A*2402,1101 B*3902,5201 Cw*0702,1202	NS3	1375–1385	FYGKAIPIEAI	n.d.
Pt14	A*2402,2601 B*4006,5401 Cw*0801,0803	E1	284–293	VFLVSQLFTF	n.d.
		E2	790–798	LYGVWPLLL	Cw*0801
		NS4	1759–1768	AFWAKHMWNF	n.d.
		NS5A	1990–1999	DFKTWLQSKL	n.d.
		NS5A	2280–2288	KFPPALPIW	A*2402
Pt15	A*2402,2601 B*3501,4002 Cw*0303,0304	NS2	910–919	PYFVRAQGLI	Cw*0303, 0304
		NS2	947–956	TYVYDHLTPL	B*4002
		NS3	1243–1252	AYAAQGYKVL	Cw*0303, 0304
Pt16	A*0206,2402 B*5201,5901 Cw*0102,1202	NS3	1443–1451	GFTGDFDSV	A*0206
Pt17	A*2402,3101 B*4801,5101 Cw*0304,0801	E2	790–798	LYGVWPLLL	Cw*0801
Pt18	A*2601,3101 B*3501,5101 Cw*0303,1402	NS5B	2456–2466	VYSTTSRSASL	n.d.

(c) CTL epitopes identified by peptides overlapping by 10 residues and spanning the entire HCV sequence [13]

	HLA class I alleles	Region	Amino acid residues	Sequence	HLA restriction
Pt19	A*2602,3101 B*5101,5102 C*1402,1502	NS3	1373–1380	IPFYGKAI	n.d.
Pt20	A*0402 B*0702,5201 C*0702,1202	E2	611–618	YPYRLWHY	n.d.
Pt21	A*1101,3101 B*6701,5101 C*0702,1402	NS5A	2290–2298	RPDYNPPLL	n.d.
Pt22	A*2402 B*5201 C*1202	NS4	1759–1768	AFWAKHMWNF	n.d.
		NS5B	2556–2564	TIMAKNEVF	n.d.
		NS5B	2803–2811	LTRDPTTPL	n.d.
Pt23	A*0201,0301 B*4402,4601 C*0102,0501	NS4	1958–1977	KRLHQWINEDCSTPCSGSWL	n.d.
Pt24	A*2402,4801 B*5201 C*0803,1202	NS3	1637–1656	LTHPITKFVMACMSADLEVV	n.d.

(d) CTL epitopes identified by peptides overlapping by 10 residues and spanning the entire HCV core sequence

Region	Amino acid residues	Sequence	HLA restriction	Reference
core	88–96	NEG(L,M,C)GWAGW	B*4403	[49]
core	28–36	GQIVGGVYL	B60	[50]

(e) CTL epitopes identified by HCV-derived synthetic peptides with binding motif of HLA-B*4403

Region	Amino acid residues	Sequence	HLA restriction	Reference
NS5a	2095–2103	AEVTQHGSY	B*4403	[16]

(f) CTL epitopes identified by comprehensive CTL induction from PBMC of HCV patients

Region	Amino acid residues	Sequence	HLA restriction	Reference
NS3	1373–1380	IPFYGKAI	B*5603	[52]